Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism NLRP3 inhibitors(NACHT, LRR and PYD domains-containing protein 3 inhibitors), VEGI inhibitors(Tumor necrosis factor superfamily member 15 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Enveda Therapeutics, Inc.Startup |
Active Organization Enveda Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Liver Diseases | Preclinical | US | Enveda Therapeutics, Inc.Startup | 01 Dec 2024 |